Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials

Published:2015-06-08 Issue:29 Volume:6 Page:28502-28512
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Mai Ruiqin¹,Zhou Songxia²,Zhong Weixiang³,Rong Siming²,Cong Zhichao²,Li Yunxian²,Xie Qizhi²,Chen Huanming²,Li Xiaoyun²,Liu Shuhui²,Cheng Yabin⁴,Huang Yuanshen⁴,Zhou Youwen⁴,Zhang Guohong²⁴

Affiliation:

1. Department of Laboratory Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China

2. Department of Pathology, Shantou University Medical College, Shantou, Guangdong, China

3. Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

4. Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NOD2 reduces the chemoresistance of melanoma by inhibiting the TYMS/PLK1 signaling axis;2024-06-14

2. Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma;Biomedicines;2024-03-17

3. Innovation durch Kombination: Wie das GKV-Finanzstabilisierungsgesetz den therapeutischen Fortschritt ausbremst;Forum;2023-09-29

4. Cancer-Associated Fibroblasts and Their Role in Cancer Progression;Interdisciplinary Cancer Research;2022

5. Screening of metabolic modulators identifies new strategies to target metabolic reprogramming in melanoma;Scientific Reports;2021-02-23